Remove Medical Remove Pharmaceutical Remove Therapy
article thumbnail

DEBRA Research, LEO Pharma Partner to Advance Treatments for EB

The Dermatology Digest

DEBRA Research GmbH, a non-profit organization focused on advancing research, advocacy, and support for those affected by Epidermolysis Bullosa (EB), and LEO Pharma are partnering to accelerate the development of new therapies for EB. There are currently no approved treatment options for EB. Together, we can do so much more.

article thumbnail

Multi-Mechanical Therapies with Topicals For Age Management

Lipgloss and Aftershave

Phyllis Hsieh is the visionary behind Conrex Pharmaceutical Corp. and the creator of SESHA SKIN THERAPY, a professional skincare brand powered by Patented enhancement technology (P.E.T ) technology. The Permeation Enhancement Technology is FDA-approved in pharmaceuticals.

article thumbnail

The Power of Tech-Nature: How Sesha Fuses Biotech with Botanical Brilliance

Lipgloss and Aftershave

Weve been singing Sesha Skin Therapy s praises for yearsand for good reason. Thanks to Sesha Skin Therapy for sponsoring this content. That groundbreaking research laid the foundation for SESHA Skin Therapy as we know it todaya skincare brand at the intersection of medical science and advanced botanical care. Translation?

article thumbnail

A Glimpse Inside the Lichen Planus Pipeline

The Dermatology Digest

Several new therapies are coming down the pike for the treatment of lichen planus, a chronic inflammatory condition that affects an estimated 1% to 2% of the global population, according to a new report from Research and Markets. Similarly, Incyte and AFYX Therapeutics are developing new therapeutics for lichen planus.

article thumbnail

Tildrakizumab (Ilumya, Sun Pharma) Improves Moderate-to-severe Nail PsO

The Dermatology Digest

Tildrakizumab-asmn (Ilumya, Sun Pharmaceutical Industries, Inc.) “As a company dedicated to developing innovative therapies which help improve quality of life for patients, these data, along with our existing data in scalp psoriasis, reinforces the benefits of ILUMYA in difficult to treat populations.”

article thumbnail

Ligand Pharmaceuticals Launches Pelthos to Accelerate Commercialization of Zelsuvmi for Molluscum; Appoints New CEO

The Dermatology Digest

Ligand Pharmaceuticals is launching Pelthos Therapeutics (Pelthos), a biopharmaceutical company, and has appointed Scott Plesha as Chief Executive Officer to accelerate the commercialization of berdazimer topical gel, 10.3% (Zelsuvmi) for the treatment of molluscum contagiosum. Zelsuvmi received a Novel Drug designation from the U.S.

article thumbnail

Benefits of the Trigger Point Massage

Hollywood Institute

Not only is this condition curable, but you aren’t restricted to opioids or other pharmaceutical treatments. Curious if , massage therapy is the right solution for your chronic pain? What is Trigger Point Therapy? What are the Benefits of Trigger Point Therapy?

Therapy 52